Coinsurance would disrupt the ability of health care practitioners to work with their patients to ascertain the best lab tests to help best diagnose new conditions, manage existing conditions, and guide therapy, which is critical for the Medicare population as they often have multiple comorbidities. Currently, since there is no cost-sharing, patients who need more…
Coinsurance would disrupt the ability of health care practitioners to work with their patients to ascertain the best lab tests to help best diagnose new conditions, manage existing conditions, and guide therapy, which is critical for the Medicare population as they often have multiple comorbidities. Currently, since there is no cost-sharing, patients who need more lab tests due to more complicated health conditions have no greater financial risk than patients those with less complex conditions when receiving their lab results – and a patient may not know whether their condition is simple or complex when they first see a doctor. Despite this common-sense approach, some policy-makers calling for entitlement reform and deficit reduction have proposed putting into place a new 20% patient coinsurance for clinical laboratory services as an attempt to make Medicare beneficiaries more aware of health care costs. In real life, coinsurance for lab services will dis-incentivize Medicare beneficiaries from receiving timely and life-saving clinical lab tests, thus increasing health care costs through worse outcomes, and would drastically increase the cost of providing lab services through generating millions of new patient bills.
-
ACLA Response to Cures 2.0
-
ACLA Files A Motion for Summary Judgment Against HHS In ACLA v. Azar
Washington, D.C. — Following a favorable decision on a jurisdictional question issued by the U.S. Court of Appeals for the D.C. Circuit, the American Clinical Laboratory Association ... Read More -
More than 60 Leading Health Care Organizations Call on CMS to Maintain Coverage for Medically Necessary Cancer Testing
Overly broad interpretation of national coverage determination for next generation sequencing restricts Medicare beneficiary access to vital testing and adversely impacts cancer care WASHINGTON, DC ... Read More -
ACLA Urges Summary Judgment from District Court on Lawsuit Against HHS
Lawsuit targets HHS’ unlawful implementation of 2014 Medicare legislation, regulation that would jeopardize beneficiaries’ access to critical lab services Washington, D.C. – With millions of ... Read More -
ACLA VS. AZAR – Reply in Support of Motion for Summary Judgment
-
ACLA Supportive of CMS Revisions to National Coverage Determination on the Use of Next Generation Sequencing in Cancer
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) expressed support today for revisions made by the Centers for Medicare and Medicaid Services (CMS) to ... Read More -
ACLA Evaluating CMS’ Final National Coverage Determination on Next Generation Sequencing
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) stated that it is reviewing the Centers for Medicare & Medicaid Services (CMS) final National Coverage ... Read More -
ACLA Leads Clinical Laboratory Community in Urging CMS to Address State Medicaid Rate Cuts for Lab Services
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) along with a dozen clinical laboratory stakeholders sent a letter to Centers for Medicare and Medicaid ... Read More -
Rep. Diana DeGette to Open ACLA 2018 Annual Meeting with a “View from Capitol Hill”
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) announced today that Rep. Diana DeGette (D-CO) will open the organization’s annual meeting on March 6th ... Read More -
ACLA Submits Comments on Next Generation Sequencing National Coverage Determination
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) today submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed national ... Read More